Table 3.
Agent | Phase | Disease |
---|---|---|
Oblimersen sodium | 2 | FL, DLBCL, WM, MM, NHL |
3 | MM | |
Obatoclax mesylate | 1 | MCL |
2 | MDS, FL, HL | |
ABT-263 | 2 | CLL, FL (combined with rituximab) |
CLL, chronic lymphocytic leukemia; DLBCL, diffuse large B-cell lymphoma; FL, follicular lymphoma; HL, Hodgkin’s lymphoma; MCL, mantle cell lymphoma; MDS, myelodysplastic syndrome; MM, multiple myeloma; NHL, non-Hodgkin’s lymphoma; WM, Waldenstrom’s macroglobulinemia